Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Non-Current Assets (2016 - 2025)

Ani Pharmaceuticals' Other Non-Current Assets history spans 14 years, with the latest figure at $13.7 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 12.16% year-over-year to $13.7 million; the TTM value through Dec 2025 reached $13.7 million, up 12.16%, while the annual FY2025 figure was $13.7 million, 12.16% up from the prior year.
  • Other Non-Current Assets for Q4 2025 was $13.7 million at Ani Pharmaceuticals, up from $12.5 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $16.1 million in Q3 2023 and bottomed at $5.0 million in Q1 2021.
  • The 5-year median for Other Non-Current Assets is $11.4 million (2022), against an average of $10.1 million.
  • The largest annual shift saw Other Non-Current Assets surged 171.42% in 2023 before it tumbled 35.82% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $5.0 million in 2021, then soared by 127.17% to $11.4 million in 2022, then rose by 6.26% to $12.1 million in 2023, then grew by 1.23% to $12.2 million in 2024, then rose by 12.16% to $13.7 million in 2025.
  • Per Business Quant, the three most recent readings for ANIP's Other Non-Current Assets are $13.7 million (Q4 2025), $12.5 million (Q3 2025), and $8.2 million (Q2 2025).